Bristol-Myers Squibb - BMY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $61.18
Forecasted Upside: 25.21%
Number of Analysts: 19
Breakdown:
1 Sell Ratings
15 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$48.86 As of 04/24/2024 05:00 PM ET

▼ -0.13 (-0.27%)

1 month | 3 months | 12 months

Get New Bristol-Myers Squibb Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMY

^$61.18

▲ +25.21% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $61.18, with a high forecast of $85.00 and a low forecast of $50.00. The average price target represents a 25.21% upside from the last price of $48.86.

Current Consensus is Hold

The current consensus among 19 investment analysts is to hold stock in Bristol-Myers Squibb. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

11/1/2022

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

1/30/2023

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

4/30/2023

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

7/29/2023

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

10/27/2023

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

1/25/2024

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

3/25/2024

0 strong buy ratings
3 buy ratings
15 hold ratings
1 sell ratings

Ratings as of

4/24/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2024	Wells Fargo & Company	Boost Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00	Low
4/1/2024	William Blair	Reiterated Rating	Market Perform		Low
3/11/2024	Societe Generale	Downgrade	Buy ➝ Hold		Low
2/6/2024	Wells Fargo & Company	Lower Target	Equal Weight ➝ Equal Weight	$58.00 ➝ $51.00	Low
2/6/2024	Redburn Atlantic	Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00	Low
1/3/2024	Bank of America	Downgrade	Buy ➝ Neutral	$68.00 ➝ $60.00	Low
12/27/2023	Bank of America	Lower Target	Buy ➝ Buy	$72.00 ➝ $68.00	Low
11/15/2023	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$68.00 ➝ $55.00	Low
11/9/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$55.00	Low
11/2/2023	Daiwa Capital Markets	Downgrade	Outperform ➝ Neutral	$68.00 ➝ $54.00	Low
10/30/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$81.00 ➝ $69.00	Low
10/27/2023	Morgan Stanley	Lower Target	Underweight ➝ Underweight	$56.00 ➝ $50.00	Low
10/27/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $51.00	Low
10/27/2023	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$60.00	Low
10/27/2023	William Blair	Downgrade	Outperform ➝ Market Perform		Low
10/27/2023	HSBC	Upgrade	Reduce ➝ Hold	$55.00 ➝ $53.00	Low
10/20/2023	UBS Group	Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $60.00	Low
10/11/2023	Morgan Stanley	Lower Target	Underweight ➝ Underweight	$57.00 ➝ $56.00	Low
10/9/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$75.00	Low
10/6/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$84.00	Low
10/2/2023	Barclays	Lower Target		$62.00 ➝ $60.00	Low
9/15/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$75.00	Low
9/15/2023	TD Cowen	Lower Target	Market Perform ➝ Market Perform	$80.00 ➝ $66.00	Low
9/15/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$84.00	Low
7/28/2023	Wells Fargo & Company	Lower Target	Equal Weight	$78.00 ➝ $65.00	Low
7/28/2023	BMO Capital Markets	Lower Target	Outperform	$87.00 ➝ $79.00	Low
7/28/2023	Bank of America	Lower Target	Buy	$85.00 ➝ $80.00	Low
7/28/2023	Atlantic Securities	Lower Target	Overweight	$90.00 ➝ $85.00	Low
7/28/2023	Barclays	Lower Target	Equal Weight	$64.00 ➝ $62.00	Low
7/19/2023	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight	$59.00 ➝ $59.00	Low
7/19/2023	Cantor Fitzgerald	Lower Target	Overweight	$88.00 ➝ $85.00	Low
7/18/2023	BMO Capital Markets	Lower Target		$92.00 ➝ $87.00	Low
7/14/2023	HSBC	Initiated Coverage	Reduce	$56.00	Low
7/12/2023	Credit Suisse Group	Lower Target		$72.00 ➝ $66.00	Low
7/11/2023	Barclays	Lower Target		$65.00 ➝ $64.00	Low
7/10/2023	SVB Leerink	Reiterated Rating	Market Perform		Low
7/10/2023	SVB Securities	Initiated Coverage	Market Perform	$66.00	Low
6/28/2023	Daiwa Capital Markets	Initiated Coverage	Outperform	$70.00	Low
5/1/2023	Barclays	Lower Target		$66.00 ➝ $65.00	Low
4/28/2023	51job	Reiterated Rating	Maintains		Low
4/28/2023	Credit Suisse Group	Lower Target		$78.00 ➝ $72.00	Low
4/21/2023	Bank of America	Boost Target	Buy	$82.00 ➝ $85.00	Low
3/6/2023	Jefferies Financial Group	Initiated Coverage	Hold	$62.00	Low
2/3/2023	Morgan Stanley	Boost Target	Underweight	$60.00 ➝ $62.00	Low
2/3/2023	Atlantic Securities	Boost Target	Overweight	$88.00 ➝ $90.00	N/A
1/17/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$95.00	Low
1/3/2023	Wells Fargo & Company	Boost Target	Equal Weight	$70.00 ➝ $78.00	Low
11/17/2022	Credit Suisse Group	Initiated Coverage	Neutral	$78.00	Low
11/10/2022	Atlantic Securities	Boost Target	Overweight	$85.00 ➝ $88.00	Low
10/27/2022	Morgan Stanley	Lower Target	Underweight	$61.00 ➝ $60.00	Low
10/27/2022	Atlantic Securities	Lower Target	Overweight	$87.00 ➝ $85.00	Low
10/12/2022	Barclays	Lower Target	Equal Weight	$69.00 ➝ $66.00	Low
10/10/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
9/27/2022	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$85.00	Low
9/14/2022	Berenberg Bank	Downgrade	Buy ➝ Hold	$82.00 ➝ $76.00	Low
9/12/2022	BMO Capital Markets	Boost Target	Outperform	$92.00 ➝ $94.00	Low
9/12/2022	Atlantic Securities	Boost Target	Overweight	$83.00 ➝ $87.00	Low
7/28/2022	Atlantic Securities	Boost Target	Overweight	$82.00 ➝ $83.00	Low
7/28/2022	JPMorgan Chase & Co.	Boost Target		$80.00 ➝ $85.00	Low
7/27/2022	UBS Group	Boost Target	Outperform	$73.00	Low
6/6/2022	Bank of America	Boost Target	Buy ➝ Buy	$78.00 ➝ $80.00	Low
6/3/2022	Citigroup	Reiterated Rating	Buy	$90.00	Low
6/3/2022	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
5/26/2022	Citigroup	Boost Target	Buy	$75.00 ➝ $90.00	Low
5/17/2022	Wells Fargo & Company	Boost Target	Equal Weight	$65.00 ➝ $70.00	Medium
5/2/2022	Truist Financial	Boost Target		$76.00 ➝ $81.00	Low
5/2/2022	BMO Capital Markets	Boost Target		$87.00 ➝ $92.00	Low
5/2/2022	Guggenheim	Boost Target		$72.00 ➝ $80.00	Low
5/2/2022	Barclays	Boost Target		$66.00 ➝ $68.00	Low
4/6/2022	Morgan Stanley	Lower Target	Equal Weight ➝ Underweight	$66.00 ➝ $64.00	Low
3/30/2022	BMO Capital Markets	Boost Target	Outperform	$74.00 ➝ $81.00	Low
3/2/2022	Wells Fargo & Company	Boost Target	Equal Weight	$60.00 ➝ $65.00	Low
12/17/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$72.00	Medium
12/8/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$58.00	Low
11/18/2021	BMO Capital Markets	Initiated Coverage	Outperform	$72.00	High
11/1/2021	Argus	Downgrade	Buy ➝ Hold	$49.00	Low
10/28/2021	Barclays	Lower Target	Equal Weight	$68.00 ➝ $66.00	Low
10/12/2021	Morgan Stanley	Lower Target	Equal Weight	$71.00 ➝ $66.00	Low
10/11/2021	Berenberg Bank	Lower Target	Buy	$75.00 ➝ $71.00	Low
10/8/2021	Barclays	Lower Target	Equal Weight	$71.00 ➝ $68.00	High
7/29/2021	Morgan Stanley	Boost Target	Equal Weight	$62.00 ➝ $71.00	Low
7/28/2021	Truist Financial	Initiated Coverage	Buy	$74.00	Low
7/28/2021	Bank of America	Reiterated Rating	Buy		High
5/6/2021	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$62.00	Low
4/30/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$70.00 ➝ $62.00	Low
4/13/2021	Truist Financial	Upgrade	Hold ➝ Buy		Low
12/15/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High
11/30/2020	Smith Barney Citigroup	Boost Target		$73.00 ➝ $77.00	Low
11/16/2020	Societe Generale	Upgrade	Hold ➝ Buy	$76.00	Low
11/10/2020	Sanford C. Bernstein	Reiterated Rating	Market Perform	$72.00	Low
11/6/2020	Gabelli	Downgrade	Buy ➝ Hold		Low
10/23/2020	Truist Financial	Initiated Coverage	Hold	$65.00	Medium
10/19/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$70.00	Medium
10/16/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$74.00 ➝ $78.00	Low
9/29/2020	Berenberg Bank	Initiated Coverage	Buy	$73.00	Low
9/25/2020	Raymond James	Reiterated Rating	Buy		Low
9/22/2020	Raymond James	Boost Target	Outperform	$75.00 ➝ $78.00	Medium
8/12/2020	Morgan Stanley	Boost Target	Overweight	$64.00 ➝ $66.00	Low
7/28/2020	Raymond James	Initiated Coverage	Outperform	$75.00	Medium
7/26/2020	Cfra	Reiterated Rating	Buy	$70.00	Low
6/2/2020	Cantor Fitzgerald	Boost Target		$68.00 ➝ $88.00	Low
6/1/2020	William Blair	Reiterated Rating	Buy		Low
5/15/2020	Bank of America	Reiterated Rating	Buy	$80.00	Low
5/15/2020	William Blair	Reiterated Rating	Buy		High
5/7/2020	Cfra	Boost Target	Buy	$69.00 ➝ $70.00	Low
4/2/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$64.00	Low
4/1/2020	Bank of America	Reiterated Rating	Buy	$75.00	Low
3/23/2020	Societe Generale	Downgrade	Buy ➝ Hold	$50.00	High
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$69.00	High
2/14/2020	William Blair	Reiterated Rating	Buy		Low
1/6/2020	Citigroup	Upgrade	Neutral ➝ Buy	$73.00	Low
12/13/2019	William Blair	Reiterated Rating	Buy		Low
12/13/2019	Argus	Upgrade	Hold ➝ Buy	$80.00	Medium
11/27/2019	Gabelli	Initiated Coverage	Buy		Medium
11/25/2019	Mizuho	Initiated Coverage	Buy		Medium
11/22/2019	Morgan Stanley	Initiated Coverage	Equal Weight	$60.00	Low
11/18/2019	William Blair	Reiterated Rating	Outperform		High
11/1/2019	Wells Fargo & Company	Set Target	Hold	$110.00	Low
11/1/2019	SVB Leerink	Set Target	Hold	$115.00	N/A
11/1/2019	Wolfe Research	Set Target	Buy	$66.00	N/A
11/1/2019	Standpoint Research	Downgrade	Buy ➝ Hold		Low
11/1/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$101.00	Low
10/23/2019	UBS Group	Boost Target	Neutral	$51.00 ➝ $53.00	Medium
10/20/2019	Mizuho	Reiterated Rating	Hold	$100.00	Low
10/16/2019	Bank of America	Initiated Coverage	Buy	$60.00	Medium
10/10/2019	Bank of America	Boost Target	Neutral	$49.00 ➝ $50.00	Low
9/13/2019	JPMorgan Chase & Co.	Set Target	Buy	$62.00	Low
9/3/2019	Bank of America	Boost Target	Neutral	$46.00 ➝ $49.00	Low
8/19/2019	Mizuho	Downgrade	Buy ➝ Neutral	$103.00 ➝ $100.00	Low
8/14/2019	Atlantic Securities	Upgrade	Neutral ➝ Overweight	$63.00	High
7/30/2019	Cowen	Reiterated Rating	Hold	$102.00	Low
7/3/2019	Mizuho	Reiterated Rating	Buy	$103.00	Low
6/25/2019	Mizuho	Reiterated Rating	Buy	$103.00	Low
6/13/2019	UBS Group	Lower Target	Neutral	$55.00 ➝ $51.00	Low
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$54.00	High
5/20/2019	Argus	Downgrade	Buy ➝ Hold	$46.36	Low
5/16/2019	Mizuho	Reiterated Rating	Buy	$103.00	Low
5/3/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$62.00	High
5/3/2019	Barclays	Downgrade	Overweight ➝ Equal Weight	$102.00	Medium
5/3/2019	Barclays	Upgrade	Equal Weight ➝ Overweight	$53.00 ➝ $55.00	High

(Data available from 4/24/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

28 very positive mentions
26 positive mentions
4 negative mentions
9 very negative mentions

Mentions as of

9/27/2023

34 very positive mentions
46 positive mentions
11 negative mentions
7 very negative mentions

Mentions as of

10/27/2023

20 very positive mentions
31 positive mentions
16 negative mentions
11 very negative mentions

Mentions as of

11/26/2023

49 very positive mentions
46 positive mentions
8 negative mentions
12 very negative mentions

Mentions as of

12/26/2023

48 very positive mentions
39 positive mentions
10 negative mentions
5 very negative mentions

Mentions as of

1/25/2024

58 very positive mentions
54 positive mentions
17 negative mentions
4 very negative mentions

Mentions as of

2/24/2024

42 very positive mentions
52 positive mentions
9 negative mentions
3 very negative mentions

Mentions as of

3/25/2024

66 very positive mentions
65 positive mentions
11 negative mentions
3 very negative mentions

Mentions as of

4/24/2024

Current Sentiment

Recent Stories by Sentiment

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $48.86

$48.55

$49.05

50 Day Range

MA: $51.22

$47.83

$54.40

52 Week Range

Now: $48.86

$47.58

$70.93

Volume

16,032,247 shs

Average Volume

15,490,699 shs

Market Capitalization

$99.03 billion

P/E Ratio

12.66

Dividend Yield

4.88%

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Bristol-Myers Squibb?: The following Wall Street analysts have issued stock ratings on Bristol-Myers Squibb in the last twelve months: 51job, Inc., Atlantic Securities, Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Credit Suisse Group AG, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Morgan Stanley, Redburn Atlantic, Societe Generale, StockNews.com, SVB Leerink LLC, SVB Securities, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BMY.
What is the current price target for Bristol-Myers Squibb?: 17 Wall Street analysts have set twelve-month price targets for Bristol-Myers Squibb in the last year. Their average twelve-month price target is $61.18, suggesting a possible upside of 24.8%. Atlantic Securities has the highest price target set, predicting BMY will reach $85.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $50.00 for Bristol-Myers Squibb in the next year.
View the latest price targets for BMY.
What is the current consensus analyst rating for Bristol-Myers Squibb?: Bristol-Myers Squibb currently has 1 sell rating, 15 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BMY, but not buy more shares or sell existing shares.
View the latest ratings for BMY.
What other companies compete with Bristol-Myers Squibb?: Other companies that are similar to Bristol-Myers Squibb include Zoetis, Pfizer, AbbVie, Merck & Co., Inc. and Johnson & Johnson. Learn More about companies similar to Bristol-Myers Squibb.
How do I contact Bristol-Myers Squibb's investor relations team?: Bristol-Myers Squibb's physical mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is (212) 546-4000 and its investor relations email address is [email protected]. The official website for Bristol-Myers Squibb is www.bms.com. Learn More about contacing Bristol-Myers Squibb investor relations.

Bristol-Myers Squibb - BMY Stock Price Target and Predictions

Analyst Price Target for BMY

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.66 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Bristol-Myers Squibb?

What is the current price target for Bristol-Myers Squibb?

What is the current consensus analyst rating for Bristol-Myers Squibb?

What other companies compete with Bristol-Myers Squibb?

How do I contact Bristol-Myers Squibb's investor relations team?